Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 17.78 USD -0.06% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Innoviva Inc?
Write Note

Net Margin
Innoviva Inc

18.3%
Current
55%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.3%
=
Net Income
64.6m
/
Revenue
352.7m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Innoviva Inc
NASDAQ:INVA
1.1B USD
18%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
17%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
19%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
13%
CH
Novartis AG
SIX:NOVN
171.5B CHF
35%
US
Pfizer Inc
NYSE:PFE
151.5B USD
7%
Country US
Market Cap 1.1B USD
Net Margin
18%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Innoviva Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

In the heart of Silicon Valley, Innoviva Inc. has carved out a niche within the pharmaceutical landscape, balancing the art of innovation with the demands of modern healthcare economics. Initially emerging as a dynamic player in drug development, Innoviva made a strategic pivot to focus on the monetization and management of its royalties and collaborations. The company's primary revenue stream flows from partnerships with GlaxoSmithKline (GSK), stemming from co-developed respiratory treatments like the inhaled medications Trelegy and Anoro Ellipta. These partnerships provide Innoviva with steady royalty income based on product sales, allowing it to operate with a lean but effective business model, focusing on maximizing value from its existing assets rather than pursuing the expensive and risky path of drug discovery and development. Beyond merely basking in the comfort of predictable cash flows, Innoviva has tactically reinvested its earnings to fuel further growth and diversification. The company has been channeling resources into acquiring new assets and entering joint ventures that align with its core expertise and long-term vision. This approach not only broadens its portfolio but also hedges against the inherent risks associated with dependency on a limited number of revenue sources. By leveraging its financial strength and strategic partnerships, Innoviva has positioned itself as a nimble player in the pharmaceutical sector, adept at extracting maximum value through prudent financial management and strategic foresight.

INVA Intrinsic Value
22.34 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.3%
=
Net Income
64.6m
/
Revenue
352.7m
What is the Net Margin of Innoviva Inc?

Based on Innoviva Inc's most recent financial statements, the company has Net Margin of 18.3%.